Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast in children and adolescents with fibrosing interstitial lung disease
CTR20262222Phase 3Active
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nerandomilast in pulmonary fibrosis (PF), sponsored by Boehringer Ingelheim. Started Aug 2026; status: active.
02
Drugs
nerandomilast
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on CTR20262222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262222.